

INTERCEPT PHARMACEUTICALS INC  
Form 8-K  
July 11, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 11, 2016**

**INTERCEPT PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

|  |                     |                            |
|--|---------------------|----------------------------|
| <b>Delaware</b><br><b>(state or other jurisdiction</b> | <b>001-35668</b>    | <b>22-3868459</b>          |
| <b>of incorporation)</b>                               | <b>(Commission</b>  | <b>(I.R.S. Employer</b>    |
|  | <b>File Number)</b> | <b>Identification No.)</b> |

**450 W. 15<sup>th</sup> Street, Suite 505**

**New York, New York**  
**(Address of principal executive offices)**

**10011**

**(Zip Code)**

**Registrant's telephone number, including area code: (646) 747-1000**

**(Former name or former address, if changed since last report)**

Edgar Filing: INTERCEPT PHARMACEUTICALS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ..Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On July 11, 2016, Intercept Pharmaceuticals, Inc. (the “Company”) announced that Lisa Bright will transition from her position as Chief Commercial and Corporate Affairs Officer and become President, International, effective immediately. The transition is being effected to provide additional focus to the Company’s growing international operations and its plans to seek marketing approval for obeticholic acid in primary biliary cholangitis in target markets outside of the United States, starting with Europe in late 2016.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERCEPT PHARMACEUTICALS, INC.

Dated July 11, 2016 /s/ Mark Pruzanski  
Mark Pruzanski, M.D.

President and Chief Executive Officer